Urbanova Anna, Medvedova Ivana, Kertys Martin, Mikolka Pavol, Kosutova Petra, Mokra Daniela, Mokrý Juraj
a Department of Pharmacology , Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava , Martin , Slovakia.
b Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava , Martin , Slovakia.
Exp Lung Res. 2017 Nov-Dec;43(9-10):407-416. doi: 10.1080/01902148.2017.1386735. Epub 2017 Dec 8.
Chronic obstructive diseases of airways associated with cough and/or airway smooth muscle hyperresponsiveness are usually treated with bronchodilating and anti-inflammatory drugs. Recently, selective phosphodiesterase (PDE) 4 inhibitors have been introduced into the therapy of chronic obstructive pulmonary disease. Several studies have demonstrated their ability to influence the airway reactivity and eosinophilic inflammation by increasing the intracellular cAMP concentrations also in bronchial asthma. Furthermore, the expression of PDE5 in several immune cells suggests perspectives of PDE5 inhibitors in the therapy of inflammation, as well.
The aim of this study was to assess the dose-dependent effects of PDE4 and PDE5 inhibitors in allergic inflammation. Therefore, the effects of 7-days administration of PDE4 inhibitor roflumilast and PDE5 inhibitor tadalafil at two different doses in experimentally-induced allergic inflammation were evaluated.
In the study, male adult guinea pigs were used. Control group was non-sensitized. Other animals were sensitized with ovalbumin over two weeks and thereafter treated intraperitoneally for 7 days with roflumilast or tadalafil (daily dose 0.5 mg/kg or 1.0 mg/kg b.w.), or with vehicle.
Both roflumilast and tadalafil reduced specific airway resistance after nebulization of histamine (marker of in vivo airway reactivity) at both doses used. The in vitro airway reactivity to cumulative doses of acetylcholine was significantly reduced for roflumilast at higher dose, predominantly in the lung tissue strips. Histamine-induced contractile responses were significantly influenced in both lung and tracheal tissue strips, predominantly at the higher doses. Tadalafil led to a decrease in contractile responses induced by both acetylcholine and histamine, with more significant effects in the lung tissue strips. These changes were associated with decreased numbers of circulating leukocytes and eosinophils and concentrations of interleukin (IL)-4, IL-5 and TNF-α in the lung homogenate.
The selective PDE4 and PDE5 inhibitors alleviated allergic airway inflammation, with more significant effects at the higher doses.
与咳嗽和/或气道平滑肌高反应性相关的慢性气道阻塞性疾病通常用支气管扩张药和抗炎药治疗。最近,选择性磷酸二酯酶(PDE)4抑制剂已被引入慢性阻塞性肺疾病的治疗中。多项研究表明,它们还能通过增加支气管哮喘患者细胞内cAMP浓度来影响气道反应性和嗜酸性粒细胞炎症。此外,几种免疫细胞中PDE5的表达也提示了PDE5抑制剂在炎症治疗中的前景。
本研究旨在评估PDE4和PDE5抑制剂在过敏性炎症中的剂量依赖性作用。因此,评估了在实验性诱导的过敏性炎症中,以两种不同剂量连续7天给予PDE4抑制剂罗氟司特和PDE5抑制剂他达拉非的效果。
本研究使用成年雄性豚鼠。对照组未致敏。其他动物用卵清蛋白致敏两周,此后腹腔注射罗氟司特或他达拉非7天(每日剂量0.5mg/kg或1.0mg/kg体重),或注射赋形剂。
在所用的两种剂量下,罗氟司特和他达拉非雾化组胺后(体内气道反应性标志物)均降低了特异性气道阻力。罗氟司特高剂量时,体外对累积剂量乙酰胆碱的气道反应性显著降低,主要在肺组织条中。组胺诱导的收缩反应在肺和气管组织条中均受到显著影响,主要在高剂量时。他达拉非导致乙酰胆碱和组胺诱导的收缩反应均降低,在肺组织条中的作用更显著。这些变化与循环白细胞和嗜酸性粒细胞数量减少以及肺匀浆中白细胞介素(IL)-4、IL-5和肿瘤坏死因子-α浓度降低有关。
选择性PDE4和PDE5抑制剂减轻了过敏性气道炎症,高剂量时效果更显著。